Pharmakotherapie der ADHS im Erwachsenenalter bei komorbider Depression

Zusammenfassung

Anliegen Die Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) hat aufgrund ihrer hohen Prävalenz von 2 - 6 % im Erwachsenenalter und der oft ausgeprägten klinischen Symptomatik große praktische Relevanz. Komorbide Störungen sind häufig. Methode Es wird ein Überblick über Diagnostik und differenzierte Pharmakotherapie der ADHS bei komorbider Depression gegeben. Ergebnisse und Schlussfolgerungen Die Depression hat als komorbide Störung bei ADHS hinsichtlich Differenzialdiagnostik und differenzierter Therapiekonzepte eine große klinische Bedeutung. Für die Kombination beider Erkrankungen gibt es gute psychotherapeutische und pharmakologische Behandlungsverfahren.

Abstract

Objective Attention-deficit/hyperactivity disorder (ADHD) is a common disorder with a high prevalence of 2 - 6 % in adults. The often distinctive clinical symptomatology has a great practical relevance and the diagnostic demarcation of other psychiatric illnesses can be difficult which underlines the necessity of a differential and careful diagnosis. ADHD is a risk factor for comorbid disorders like anxiety, personality disorders and addiction. Comorbid depression is also frequent and has an important meaning in the differential diagnostic process. Methods A review was made about diagnostics and pharmacotherapy of ADHD with comorbid depression. Results and Conclusions For the combination treatment of ADHD with comorbid depression there are good pharmacological procedures of treatment. Here in particular modern antidepressants with noradrenergic or noradrenergic-serotonergic active principles play an important role. Very important is an exact diagnosis and differentiated treatment of ADHD, i. e. a „multimodal therapy” using pharmacological and psychotherapeutic concepts.

ADHS - komorbide Störung - Depression - Pharmakotherapie

ADHD - comorbid disorders - depression - pharmacotherapy

Literatur

• 1 Barkley R A. Advancing age, declining ADHD.  Am J Psychiatry. 1997;  154 1323-1325
• 2 Wender P H. Attention-deficit disorder in adults. New York; Oxford University Press 1995
• 3 Kessler R C, Adler L, Barkley R. et al . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.  Am J Psychiatry. 2006;  163 716-723
• 4 Faraone S V, Biederman J. Neurobiology of attention-deficit hyperactivity disorder.  Biol Psychiatry. 1998;  44 951-958
• 5 Smalley S L, Bailey J N, Palmer C G. et al . Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder.  Mol Psychiatry. 1998;  3 427-430
• 6 Ernst M, Zametkin A J, Matochik J A, Jons P H, Cohen R M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18] fluorodopa positron emission tomographic study.  J Neurosci. 1998;  18 5901-5907
• 7 Dougherty D D, Bonab A A, Spencer T J, Rauch S L, Madras B K, Fischman A J. Dopamine transporter density in patients with attention deficit hyperactivity disorder.  Lancet. 1999;  354 2132-2133
• 8 Dresel S HJ, Kung M P, Huang X F, Plössl K, Hou C, Meegalla S K, Patselas G. et al . Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.  J Nucl Med. 1999;  40 660-666
• 9 Krause K H, Dresel S H, Krause J, Kung H F, Tatsch K, Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder.  Int J Neuropsychopharmacol. 2002;  5 111-113
• 10 Gainetdinov R R, Wetsel W C, Jones S R, Levin E D, Jaber M, Caron M G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.  Science. 1999;  283 397-401
• 11 Edel M A, Schmidt K. Phobische Angst und Persönlichkeitsstörungen sowie soziale Beeinträchtigung ambulanter erwachsener Patienten mit Aufmerksamkeitsdefizit/Hyperaktivitätsstörungen.  Nervenheilkunde. 2003;  22 415-418
• 12 Biederman J, Faraone S V, Keenan K. et al . Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples.  Arch Gen Psychiatry. 1992;  49 728-738
• 13 Krause J, Krause K H. ADHS im Erwachsenenalter. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen. Stuttgart, New York; Schattauer 2005
• 14 Biederman J, Faraone S V, Spencer T. et al . Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.  Am J Psychiatry. 1993;  150 1792-1798
• 15 MTA Cooperative Group . A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.  Arch Gen Psychiatry. 1999;  56 1073-1086
• 16 Hesslinger B, Tebartz van Elst L, Mochan F, Ebert D. A psychopathological study into the relationship between attention deficit hyperactivity disorder in adult patients and recurrent brief depression.  Acta Psychiatr Scand. 2003;  107 385-389
• 17 Spencer T J. Our new understanding of the prevalence, impairments, comorbidity and treatment of adults with ADHD. 157th Annual Meeting,. New York; American Psychiatric Association 2004
• 18 Elia J, Ambrosini P J, Rapoport J L. Treatment of attention-deficit-hyperactivity disorder.  N Engl J Med. 1999;  340 780-788
• 19 Wilens T E. Drug therapy for adults with attention-deficit hyperactivity disorder.  Drugs. 2003;  63 2395-2411
• 20 Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial.  J Am Acad Child Adolesc Psychiatry.. 1991;  30 762-767
• 21 Schulz S C. Atypicals in borderline personality disorders. 157th Annual Meeting. New York; American Psychiatric Association 2004
• 22 Adler L A, Resnick S, Kunz M, Devinsky O. Open-label trial of venlafaxine in adults with attention deficit disorder.  Psychopharmacol Bull. 1995;  31 785-788
• 23 Findling R L, Schwartz M A, Flannery D J, Manos M J. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.  J Clin Psychiatry. 1996;  57 184-189
• 24 Hornig-Rohan M, Amsterdam J D. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 585-589
• 25 Wilens T E, Biederman J, Mick E, Spencer T J. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder.  J Nerv Ment Dis. 1995;  183 48-50
• 26 Wilens T E, Biederman J, Prince J. et al . Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.  Am J Psychiatry. 1996;  153 1147-1153
• 27 Wilens T E, Spencer T J, Biederman J. et al . A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.  Am J Psychiatry. 2001;  158 282-288
• 28 Kuperman S, Perry P J, Gaffney G R. et al . Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.  Ann Clin Psychiatry. 2001;  13 129-134
• 29 Michelson D, Allen A J, Busner J. et al . Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.  Am J Psychiatry. 2002;  159 1896-1901
• 30 Michelson D, Faries D, Wernicke J. et al . Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.  Pediatrics. 2001;  108 E83
• 31 Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone S V, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.  J Child Adolesc Psychopharmacol. 2001;  11 251-265
• 32 Kratochvil C J, Newcorn J H, Arnold L E, Duesenberg D, Emslie G J, Quintana H, Sarkis E H, Wagner K D, Gao H, Michelson D, Biederman J. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.  J Am Acad Child Adolesc Psychiatry. 2005;  44 915-924